Bacopa monnieri for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Bacopa monnieri may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed Bacopa monnieri in detail.
, Indian herb-derived phytoconstituents based antiviral formulation: An oral rinse candidate for prevention of COVID-19 outbreaks, Authorea, Inc., doi:10.22541/au.170666690.05725131/v1
Outbreaks of emerging infectious diseases continue to challenge human health. Novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has triggered a global coronavirus pandemic, namely COVID-19. Multiple variants of SARS-CoV-2 virus are circulating and raises question with respect to effectiveness of different lines of treatment such as vaccines and antiviral drugs. To find appropriate prevention/treatment, 21 plant-based ingredients were identified with antiviral properties. We pseudo typed SARS-CoV-2 on a lentiviral vector plasmid and tested the impact of five different herbal formulations in mammalian HEK293T cells. Viral inactivation assay showed that the natural extracts in herb-derived phytoconstituents based formulation, BITS-003 comprising of Bacopa monnieri, Glycyerrhiza glabra, Asparagus racemosus-wild, and Nigella sativa bear strong virucidal properties, inactivating enveloped viruses from 2log10 (or 99%) to >4log10 (or 99.99%). Moreover, bacterial and yeast cells treated with BITS-003 displayed reduced growth. Topical use of formulation as mouthwash/gargle will be effective in reducing symptoms of respiratory viral infections with a potential to decrease viral load in buccal/oral cavity. This may inhibit the coronavirus spreading to the lungs of infected person and at the same time will reduce the risk of viral transmission to other susceptible persons through micro-droplets originating from the oral cavity of the infected person.